Radiotherapy Combined With Endostatin and Capecitabine for NPC
Nasopharyngeal Carcinoma
About this trial
This is an interventional treatment trial for Nasopharyngeal Carcinoma focused on measuring Nasopharyngeal Carcinoma, Radiotherapy, Endostatin, Capecitabine
Eligibility Criteria
Inclusion Criteria:
Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO) histologically type).
Tumor staged as T3-4N1/N2-3 (according to the 8th American Joint Commission on Cancer edition).
No evidence of distant metastasis (M0). Satisfactory performance status: Karnofsky scale (KPS) > 70. Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL.
Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) <1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN.
Adequate renal function: creatinine clearance ≥60 ml/min. Patients must be informed of the investigational nature of this study and give written informed consent.
unsatisfactory tumor response (stable or progressive disease) after neoadjuvant chemotherapy (NACT)
Exclusion Criteria:
WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.
Treatment with palliative intent. Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer.
Pregnancy or lactation. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), and emotional disturbance.
satisfactory tumor response (complete response or partial response) after neoadjuvant chemotherapy (NACT)
Sites / Locations
- Zhejiang Cancer HospitalRecruiting
- the First Hospital of JiaxingRecruiting
- Jinhua Central HospitalRecruiting
- The Central Hospital of Lishui CityRecruiting
- Ningbo First HospitalRecruiting
- Ningbo Medical Center Lihuili Eastern HospitalRecruiting
- People's Hospital of QuzhouRecruiting
Arms of the Study
Arm 1
Experimental
Endostatin and Capecitabine
Patients received radiotherapy Combined With Endostatin and Capecitabine